Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
about
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerMechanisms of chemotherapy-induced behavioral toxicitiesReview of systemic therapies for locally advanced and metastatic rectal cancerA novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathyA polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in ratsMembrane transporters as mediators of Cisplatin effects and side effects.Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trialEfficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysisPhase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)Predicting acute and persistent neuropathy associated with oxaliplatin.Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathyAttenuation of activity in an endogenous analgesia circuit by ongoing pain in the ratA novel behavioral assay for measuring cold sensation in mice.Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats.Gyejigachulbu-Tang Relieves Oxaliplatin-Induced Neuropathic Cold and Mechanical Hypersensitivity in Rats via the Suppression of Spinal Glial Activation.Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy.Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in micePhase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptorsManagement of oxaliplatin-induced peripheral neuropathy.Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.Longitudinal assessment of oxaliplatin-induced neuropathy.Review article: colorectal cancer chemotherapy.Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilityNeurotoxicity caused by the treatment with platinum analogues.Molecular mechanisms of resistance and toxicity associated with platinating agents.Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.Developments in combination chemotherapy for colorectal cancer.A review of oxaliplatin and its clinical use in colorectal cancer.Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensationOxaliplatin-associated neuropathy: a review.Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial.Advances in the adjuvant treatment of colorectal cancer.Management of advanced colorectal cancer: state of the art.Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
P2860
Q24815800-66C0DEC0-00AE-4993-8496-C5371879E375Q26998870-B6D97CD3-B998-4B44-A86C-851DFB01AA31Q27021105-5FB260EE-9904-48B5-A872-5F4795B1FF4BQ28484947-697FD6C0-1236-4E24-B30D-334BB1C9662DQ28534748-530F20D3-751A-42DE-8B74-5C499AB65F34Q30446860-11B0AF37-A84F-4F2E-BD38-615483F65249Q33389165-1153340D-E88A-4C43-BF7A-F488D61BDFBDQ33604447-DD9ABB74-24D0-4AE4-9766-5F813DF83A81Q33774892-0DBA0F1E-33F4-414E-986F-335BED35BA3FQ33780411-01E73316-E9C9-4153-8CCE-0C99A7FC5920Q33800645-074F3309-DB24-4C8E-84EF-69A4112A65EFQ33841734-B1C1BC0C-5B71-4A42-867A-481F540A155AQ33873552-C993258E-17AA-4CA7-A52C-F041A9656F7BQ34133825-CA931EC2-D42F-437B-833F-1F955CC0E25EQ34267113-F27EF152-0A8F-4B28-B3C8-C4042EE3AC63Q34321665-9A75D4B5-AD58-4E7C-B70D-0ECAA4A6DE04Q34380468-AD375BB0-B5A4-4A11-8B53-C9119B3792A3Q34610876-C7A2C44F-C3EB-41F5-B09D-FCFC53B7B638Q34653461-1D1B0097-35FA-42BA-A6BD-90C5C816D2FEQ34683946-F3BBE80E-F6D8-42E5-AD25-79EE5A9F294AQ35019148-9D07510E-62F1-4335-9637-BDDA648CCC0CQ35025710-C55154E4-01A3-47A3-A88C-16B6BD0AB2C8Q35103028-B5EFEFC8-119E-4683-8761-64D56790D06EQ35160434-A269BCFE-A8CB-44F2-9024-02EC591090A8Q35166744-2F05C7C1-A1F1-4120-BE02-45D32643A64EQ35168122-B18BE1A6-BAE6-41B5-9DB6-2A77862D86FDQ35210263-A95ED09C-3971-4899-B9A2-0D4948DD0B25Q35544078-AF2B8B3B-AFF9-4C76-AEEA-17FFE2964801Q35584874-635DAFAA-C502-4D43-9067-34AD93E62895Q35692169-D62BF703-161E-46CD-AFA7-D35AD4623DABQ35758048-5FE67E6B-0993-430D-8B07-6DA9DC951263Q35815721-6CD64152-C047-4D23-AAA2-C0863AA2BB33Q35843703-EFB14E1F-17DC-472A-AFCF-03F2FC5EA9AFQ35906940-54A96548-D1DA-4019-AB86-F10B0E0E8357Q35931656-7DA412DC-F07E-418D-9292-DE4F7D1FA0AAQ35980222-4AA19F34-A643-4CF2-8DCF-1F977041507BQ36350645-0A78704F-0B04-4029-A71B-B75279CD1102Q36503798-71B5F769-A63A-46FC-8DF3-00B782607108Q36533867-9CB75D0D-2418-4E2F-9D58-0B6477D49F32Q36614800-378ECF21-70F7-4A12-AF23-B3C492AEAC9A
P2860
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical aspects and molecular ...... opment of preventive measures.
@ast
Clinical aspects and molecular ...... opment of preventive measures.
@en
type
label
Clinical aspects and molecular ...... opment of preventive measures.
@ast
Clinical aspects and molecular ...... opment of preventive measures.
@en
prefLabel
Clinical aspects and molecular ...... opment of preventive measures.
@ast
Clinical aspects and molecular ...... opment of preventive measures.
@en
P2093
P356
P1433
P1476
Clinical aspects and molecular ...... opment of preventive measures.
@en
P2093
Erick Gamelin
Laura Bossi
Laurence Gamelin
Stefan Quasthoff
P356
10.1053/SONC.2002.35525
P433
5 Suppl 15
P577
2002-10-01T00:00:00Z